XML 15 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 25, 2020
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Item
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
License And Collaboration Agreements [Line Items]                                
Revenue recognized related to upfront and milestone payments                           $ 2,364,000 $ 843,000  
Licenses revenue           $ 143,277,000 $ 112,408,000 $ 100,792,000 $ 73,278,000 $ 77,330,000 $ 55,323,000 $ 52,643,000 $ 43,919,000 429,755,000 229,214,000 $ 181,104,000
Deferred revenue           20,846,000       20,710,000       20,846,000 20,710,000 19,054,000
Licensing Revenue                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                           2,364,000 843,000 1,279,000
Product Revenue, Net                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                           $ 427,391,000 228,371,000 $ 179,825,000
Mochida | In-licenses | Research and Development Expense                                
License And Collaboration Agreements [Line Items]                                
Upfront payment                             2,700,000  
Eddingpharm | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Non-refundable up-front received         $ 15,000,000.0                      
Number of indications of the regulatory milestone events relating to the submission and approval | Item                           3    
Amounts to be received upon achievement of the regulatory milestone events                           $ 33,000,000.0    
Sales-based milestone event payment                           120,000,000.0    
Revenue recognized related to upfront and milestone payments                           300,000 100,000  
Deferred revenue           13,000,000.0       13,200,000       13,000,000.0 13,200,000  
Eddingpharm | Out-licenses | Licensing Revenue                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                           3,000,000.0 2,800,000  
Eddingpharm | Out-licenses | Maximum                                
License And Collaboration Agreements [Line Items]                                
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                           153,000,000.0    
Amounts to be received upon achievement of the regulatory milestone events                           15,000,000.0    
Sales-based milestone event payment                           50,000,000.0    
Eddingpharm | Out-licenses | Minimum                                
License And Collaboration Agreements [Line Items]                                
Amounts to be received upon achievement of the regulatory milestone events                           2,000,000.0    
Sales-based milestone event payment                           5,000,000.0    
Eddingpharm | Out-licenses | Clinical Trial Application                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment       $ 1,000,000.0                        
Biologix FZCo | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Revenue recognition period of non-refundable up-front payment       10 years                        
Biologix FZCo | Out-licenses | Product Revenue, Net                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                           700,000 100,000  
HLS | Out-licenses                                
License And Collaboration Agreements [Line Items]                                
Non-refundable up-front received     $ 5,000,000.0                          
Non-refundable milestone payment   $ 2,500,000 $ 2,500,000                          
Revenue recognized related to upfront and milestone payments                           2,100,000 600,000  
Deferred revenue           $ 7,100,000       $ 6,600,000       7,100,000 6,600,000  
Non-refundable up-front received period     6 months                          
HLS | Out-licenses | Health Canada                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment     $ 2,500,000                          
HLS | Out-licenses | Subsequent Event                                
License And Collaboration Agreements [Line Items]                                
Non-refundable milestone payment $ 2,500,000                              
HLS | Out-licenses | Licensing Revenue                                
License And Collaboration Agreements [Line Items]                                
Licenses revenue                           $ 2,900,000 $ 900,000  
HLS | Out-licenses | Maximum                                
License And Collaboration Agreements [Line Items]                                
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone     $ 53,800,000